TG Therapeutics, Inc. Opens Expansion Cohorts in Its Phase I/II Trial of TG ... PharmaLive (press release) (subscription) Coupled with the clinical activity seen in both rituximab relapsed and refractory patients across the dose levels tested thus far, we made the determination to expand the 900mg dose while we continue dose escalating. We look forward to expanding the ... |
